SynthesisNeurosurgical review2026
Endocrine and surgical outcomes after medial cavernous sinus wall resection for functioning pituitary adenomas: a systematic review and meta-analysis.
Synthesis in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functioning pituitary adenomas (FPAs) require both cytoreduction and durable endocrinological remission (ER), which is often limited by occult invasion of the medial cavernous sinus wall. Selective medial cavernous sinus wall resection (MCSWR) has emerged as a targeted approach, but its endocrine benefits and safety profile remain incompletely understood. We synthesize syndrome-specific remission, resection, recurrence, and complication rates after MCSWR in adults with FPAs. We conducted a systematic review and meta-analysis of PubMed, Scopus, and Embase through 2025, including adults with GH-, ACTH-, and prolactin-secreting adenomas who underwent intentional medial cavernous sinus wall resection as described by the original studies and had at least one postoperative endocrine outcome. Two reviewers extracted study- and tumor-level data on resection, ER, recurrence, and complications. Pooled event rates were estimated with random-effects models. Thirteen studies (11 retrospective, 2 prospective) involving 493 patients met inclusion criteria. Among 344 patients with available endocrine follow-up, pooled ER was 85% (95% CI:77-91%), and gross total resection (GTR) was 92% (95% CI:81-97%). Recurrence occurred in 6% (95% CI:3-13%). Subgroup ER rates were 87% for acromegaly, 89% for Cushing's disease, and 78% for prolactinomas, with corresponding GTR rates of 95%, 91%, and 80%. Complications were rare: ICA injury 0%, cranial nerve III and VI palsies 3% each, and postoperative CSF leak 4%. Most studies had a serious or critical risk of bias, mainly due to confounding and single-arm designs. Follow-up ranged from 9 to 30 months in contributing cohorts, with earlier series reporting ranges up to 1-49 months. MCSWR was associated with high reported ER and GTR rates, low reported recurrence, and acceptable morbidity in carefully selected patients with FPAs, particularly somatotroph and corticotroph tumors. However, the evidence mainly comes from high-volume centers and non-comparative series with limited follow-up, highlighting the need for prospective, multicenter studies with standardized endocrine endpoints, histological confirmation, and long-term follow-up.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.